

ORIGINAL RESEARCH

Tumor Characteristics Predicting Perineural Invasion in Cutaneous Squamous Cell Carcinoma Identified by Stepwise Logistic Regression Analysis

Brandon T. Beal MD^{1,2}, Maulik M. Dhandha MD^{2,3}, Melinda B. Chu MD^{2,4}, Vamsi Varra BS⁵, Eric S. Armbrrecht PhD⁶, Jordan B. Slutsky MD^{2,7}, Scott W. Fosko MD^{2,8}.

¹Department of Dermatology, Cleveland Clinic, Cleveland, OH

²Department of Dermatology, Saint Louis University, St. Louis, MO

³Maine-Dartmouth, Family Medicine Residency, Augusta, ME

⁴Onco Derm, St. Louis, MO

⁵Case Western Reserve University School of Medicine, Case Western Reserve, Cleveland, OH

⁶Saint Louis University Center for Outcomes Research, Saint Louis University, St. Louis, MO

⁷Department of Dermatology, Stony Brook Medicine, Stony Brook, NY

⁸Department of Dermatology, Mayo Clinic, Jacksonville, FL

ABSTRACT

Background: Perineural invasion (PNIInv) is a significant risk factor for metastasis and death in cutaneous squamous cell carcinoma (cSCC). Despite this known association, factors contributing to the presence of PNIInv are not well characterized.

Aims: To determine risk factors associated with the presence of PNIInv using the high-risk cSCC criteria developed by the National Comprehensive Cancer Network (NCCN).

Methods: After receiving Institutional Review Board approval for this retrospective review, the presence of NCCN high-risk factors for cSCC were recorded for patients treated at a tertiary referral academic medical center, from January 1, 2010 to March 31, 2012. Stepwise logistic regression was used to identify factors associated with the presence of PNIInv.

Results: PNIInv was present in 34 of 507 (6.7%) cSCCs. Moderately or poorly differentiated histology ($p < 0.001$, OR 6.6 [95% CI, 3.2-13.7]), acantholytic, adenosquamous, or desmoplastic subtype ($p = 0.01$, OR 1.8 [95% CI, 0.8-4.2]), and tumors in areas M ($\geq 10\text{mm}$) and H ($\geq 6\text{mm}$) ($p = 0.05$, OR 5.0 [95% CI, 1.2-21.0]) were significantly associated with the presence of PNIInv.

Conclusions: This data suggests clinicians should have a higher suspicion and may be able to identify PNIInv in high-risk cSCC based on the presence of specific high-risk factors.

INTRODUCTION

Perineural invasion (PNIInv) in cutaneous squamous cell carcinoma (cSCC) has been established as a significant independent risk

factor for metastasis and death.¹⁻⁵ Accordingly, PNIInv is included as a high-risk factor in the National Comprehensive Cancer Network's (NCCN) cSCC guidelines.⁴ While the association of PNIInv with poor outcomes is well known, factors contributing to the

presence of PNIInv in cSCC are not well characterized. Our aim was to determine risk factors associated with the presence of PNIInv using the high-risk cSCC criteria developed by the NCCN.

METHODS

After receiving Institutional Review Board approval, electronic medical records (EMR) were queried for all patients diagnosed with cSCC of the head and neck treated at a tertiary referral academic medical center from January 2010 to March 2012. Patients were seen across multidisciplinary settings including the departments of Dermatology, Otolaryngology-Head and Neck Surgery, Hematology and Oncology, Radiation Oncology, Surgical Oncology, and Plastic Surgery. Patient demographic data as well as the presence of the NCCN high-risk factors for head and neck cSCC were recorded.

NCCN defines high-risk location/size as ≥ 10 mm in area M (forehead, scalp, cheek, neck, and pretibia) and ≥ 6 mm in area H, “mask areas of the face” (central face, eyelids, eyebrows, periorbital, nose, lips [cutaneous and vermilion], chin, mandible, preauricular and postauricular skin/sulci, temple, ear), genitalia, hands, and feet.

Breslow Depth (BD) and Clark Level (CL) were available for 6 of 507 tumors (1.2%); thus, tumors were not excluded if they had incomplete BD or CL. Tumors with incomplete EMR data, other than BD or CL, were excluded. PNIInv was defined as tumor cell invasion within the perineurium or endoneurium as identified on the biopsy or excision pathology, or during Mohs Micrographic Surgery. PNIInv was determined by reviewing the dermatopathology and surgical pathology

reports. Stepwise logistic regression was used to identify NCCN cSCC high-risk factors associated with the presence of PNIInv. Alpha was set at 0.05.

RESULTS

There were a total of 520 cSCCs of the head and neck identified and 13 were excluded due to incomplete EMR data. The analysis included 507 tumors from 471 patients. PNIInv was present in 34 of 507 cSCCs (6.7%) from 34 patients (29 male and 5 female). The average age of the PNIInv cohort was 77 years (SD 13.1 years). The mean size of tumors with PNIInv was 2.6 cm (median 1.6 cm, range 0.6-8 cm) compared to a mean of 1.3 cm (median 1.0 cm, range 0.3-8.5 cm) for the overall cohort (Table 1). The majority (58.8%) of tumors with PNIInv were ≤ 2.0 cm. The most common anatomic locations of cSCC for the overall and PNIInv cohorts were the ear (19.5% vs. 14.7%), scalp (15.4% vs. 17.6%), and cheek (15.0% vs. 14.7%). Areas M (> 10 mm) and H (> 6 mm) contained 12 (35.3%) and 20 (58.8%) of cSCCs with PNIInv, respectively.

The logistic regression model identified three statistically significant NCCN high-risk factors associated with the presence of PNIInv in cSCC: moderately or poorly differentiated histology ($P < 0.001$, OR 6.6 [95% CI, 3.2-13.7]), acantholytic, adenosquamous, or desmoplastic subtype ($P = .01$, OR 1.8 [95% CI, 0.8-4.2]), and tumors fitting NCCN criteria for areas M and H ($P = .05$ OR 5.0 [95% CI, 1.2-21.0]) (Table 2).

Table 1: NCCN Patient and Tumor data.

	Overall Cohort N = 507 (%)	PNInv cohort n = 34 (%)	P value
Location/size as a high-risk feature, No. (%)	393 (77.5)	32 (94.1)	0.03
Area M >10 mm ^a , No. (%)	137 (27.0)	12 (35.3)	0.10
Area H > 6 mm ^b , No. (%)	256 (50.5)	20 (58.8)	0.41
Moderately or poorly differentiated	72 (14.2)	16 (47.1)	<.001
Acantholytic, adenosquamous or desmoplastic subtypes	76 (15.0)	8 (23.5)	0.23
Depth >2mm or Clark Level IV, V ^c , No. (%)	5 (1.0)	1 (2.9)	0.89
Rapidly growing	78 (15.4)	12 (35.3)	0.002
Poorly-defined borders	68 (13.4)	2 (5.9)	0.28
Recurrence	50 (9.9)	8 (23.5)	0.014
Immunosuppression	34 (6.7)	3 (8.8)	0.88
Site of prior radiation therapy or chronic inflammatory process	5 (1.0)	2 (5.9)	0.04
Neurological symptoms	1 (0.2)	0 (0)	1.00
Vascular Involvement ^d	1 (0.2)	1 (2.9)	0.08

PNInv, perineural invasion; No., number.

^aArea M: ≥10 mm on the forehead, scalp, cheek, neck, and pretibia.

^bArea H: ≥ 6 mm on the “mask areas of the face” (central face, eyelids, eyebrows, periorbital, nose, lips (cutaneous and vermilion), chin, mandible, preauricular and postauricular skin/sulci, temple, ear), genitalia, hands, and feet.

^cDepth or Clark Level was rarely recorded, 6 of 507 tumors.

^dPNInv and vascular invasion are considered as a single grouping for the NCCN criteria.

Table 2: Multivariable predictors of perineural invasion.

	Entire cohort N = 507 (%)	PNInv cohort n=34 (%)	P value	Odds Ratios (95% C.I.)
Moderately or poorly differentiated	72 (14.2)	16 (47.1)	<.001	6.6 (3.2-13.7)
Acantholytic, adenosquamous or desmoplastic subtypes	76 (15.0)	8 (23.5)	0.01	1.8 (0.8-4.2)
Location/size as a high-risk feature	393 (77.5)	32 (94.1)	0.05	5.0 (1.2-21.0)
Area M >10 mm ^a	137 (27.0)	12 (35.3)		
Area H > 6 mm ^b	256 (50.5)	20 (58.8)		

PNInv, perineural invasion.

^aArea M: ≥10 mm on the forehead, scalp, cheek, neck, and pretibia.

^bArea H: ≥ 6 mm on the “mask areas of the face” (central face, eyelids, eyebrows, periorbital, nose, lips (cutaneous and vermilion), chin, mandible, preauricular and postauricular skin/sulci, temple, ear), genitalia, hands, and feet.

DISCUSSION

In this study, moderately or poorly differentiated histology, acantholytic, adenosquamous, or desmoplastic subtypes, and tumors fulfilling NCCN criteria for areas M and H were significantly associated with the presence of PNInv in cSCC (Table 2). This data suggests clinicians should have a higher suspicion and may be able to identify PNInv in cSCC based on these specific high-risk factors. As independent risk factors for cSCC, tumor size, location on the face, and moderately or poorly differentiated histology have been associated with metastasis and death,¹⁻⁶ while acantholytic, adenosquamous, or desmoplastic subtypes

of cSCC have received considerably less attention in the literature.

The identification of patients with high-risk cSCC is critical to the subsequent management of these tumors, as well as improving patient outcomes. By identifying cSCCs with PNIInv and other high-risk characteristics early, prompt and aggressive management can be initiated providing patients the best outcomes possible. This includes initial treatment with complete margin assessment, such as Mohs micrographic surgery, to maximize complete tumor removal. Waiting until PNIInv is symptomatic likely means involvement of larger diameter nerves, which is associated with an aggressive clinical course.^{1-3,6}

Though further validation is needed, cSCCs with PNIInv may not possess traditional high-risk features for metastasis, such as increased size >2cm or lip location. Interestingly, in the PNIInv cohort the majority (n=20, 58.8%) were ≤2 cm and only 1 tumor was on the lip. Of note, the scalp and cheek two frequent sites for PNIInv in this analysis are classified in area M, which requires a larger tumor (≥ 10 mm) to be considered high-risk compared to area H (≥ 6 mm).

Established cSCC high-risk factors excluded from the model due to lack of statistical significance with PNIInv included the following: poorly-defined borders, recurrence, immunosuppression, site of prior radiation therapy or chronic inflammatory process, neurologic symptoms, depth > 2mm or CL IV, V, and vascular involvement (Table 1). The lack of statistical significance for many established cSCC high-risk factors was unexpected, but could be related to the characteristics of the sample or its size. The excluded factors may be rare enough in presentation not to merit inclusion in the

model or they may have been present, but were infrequently recorded. Of note, BD and CL were rarely recorded (6 of 507 tumors, 1.2%). Consequently, the minimal data on BD and CL impacted our ability to fully examine their association with PNIInv. In our experience, there are significant inter-institutional differences in the routine collection of BD and CL.

CONCLUSION

In summary, the results reported herein are informative and advocate for clinicians having a higher suspicion for PNIInv in cSCC with moderate or poor differentiation, acantholytic, adenosquamous, or desmoplastic subtypes, and those tumors in areas M (≥ 10 mm) and H (≥ 6 mm). Additionally, we identified that tumors ≤ 2cm in diameter were often (58.8%) associated with PNIInv.

Conflict of Interest Disclosures: None.

Funding: None.

Corresponding Author:

Brandon T. Beal, MD
Department of Dermatology
Cleveland Clinic
9500 Euclid Avenue, A60
Cleveland, OH
e-mail: bealb@ccf.org

References:

- 1) Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. *J Am Acad Dermatol* 1992;26(6):976-90.
- 2) Carter JB, Johnson M, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year

- cohort study. *JAMA Dermatol* 2013;149(1):35-41.
- 3) Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. *J Surg Oncol* 2012;106(7):811-5.
 - 4) "NCCN Guidelines version 1.2016 Squamous Cell Skin Cancers." National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf Accessed April 1, 2016.
 - 5) Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. *JAMA Dermatol* 2013;149(5):541-7.
 - 6) Campoli M, Brodland DG, Zitelli J. A prospective evaluation of the clinical, histologic, and therapeutic variables associated with incidental perineural invasion in cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 2014 Apr;70(4):630-6.